Sign In
Last checked at 
1 Jun 2026 07:00
01 June 2026
genedrive plc
("genedrive" or the "Company")
Block Listing Returns
The Company confirms the block listing six monthly return for the period to 31 May 2026.
Name of applicant | genedrive plc
| |||
Name of scheme | 2007 Share Option Scheme | |||
Period of return: | From: | 01 December 2025 | To: | 31 May 2026 |
Balance of unallocated securities under scheme(s) from previous return: | 131,726 shares
| |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 131,726 shares
| |||
Name of applicant | genedrive plc
| |||
Name of scheme | 2017 Share Option Scheme | |||
Period of return: | From: | 01 December 2025 | To: | 31 May 2026 |
Balance of unallocated securities under scheme(s) from previous return: | 1,150,588 shares
| |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,150,588 shares
| |||
Name of applicant | genedrive plc
| |||
Name of scheme | Unapproved Share Option Scheme | |||
Period of return: | From: | 01 December 2025 | To: | 31 May 2026 |
Balance of unallocated securities under scheme(s) from previous return: | 2,668,144 shares
| |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 2,668,144 shares
| |||
Name of contact: | Russ Shaw CFO | |||
Telephone number of contact: | +44 (0)161 989 0245 | |||
For enquires:
genedrive plc | +44 (0)161 989 0245 |
Gino Miele: CEO / Russ Shaw: CFO | https://investors.genedrive.com/s/e0025c
|
Peel Hunt LLP (Nominated Adviser and Broker) | +44 (0)20 7418 8900 |
James Steel | |
5654 & Company (Media & Investor Relations) | genedrive@5654.co.uk |
Matthew Neal | +44 (0)7917 800 011 |
Melissa Gardiner | +44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com)
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.
genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention
The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.
Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.
Follow the stocks
